Byooviz Generic Name & Formulations
Ranibizumab-nuna 10mg/mL (0.5mg); soln for oph intravitreal inj; preservative-free.
Vascular endothelial growth factor (VEGF) inhibitor.
Neovascular (wet) age-related macular degeneration (AMD). Macular edema following retinal vein occlusion (RVO). Myopic choroidal neovascularization (mCNV).
Byooviz Dosage and Administration
Give by intravitreal inj. AMD: 0.5mg once a month (approx. 28 days); or 3 monthly doses followed by less frequent dosing (less effective); or 0.5mg every 3 months after 4 monthly doses (less effective). Monitor regularly. RVO: 0.5mg once a month (approx. 28 days). mCNV: 0.5mg once a month (approx. 28 days) for up to 3 months; may retreat if needed.
Ocular or periocular infections.
Byooviz Boxed Warnings
Monitor intraocular pressure prior to and 30mins after inj. Monitor for perfusion of optic nerve head and for infection following the inj (endophthalmitis and retinal detachments possible). Pregnancy; may cause embryo-fetal toxicity. Nursing mothers.
Byooviz Adverse Reactions
Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, intraocular inflammation; rare: arterial thromboembolic events.
Byooviz Clinical Trials
Byooviz Patient Counseling